VIDEO: SMILE enhancement helps maintain epithelium in prior refractive surgery cases

NEW YORK — In a presentation at OSN New York, William F. Wiley, MD, discusses the advantages of using SMILE in prior refractive surgery cases and provides insight on specific techniques using surgical footage.
“SMILE enhancement allows for multiple approaches to maintain epithelium and thus allows for more predictable healing,” he said. “You can do a thin flap, a thick-flap LASIK, side cut only or an expanded zone cap-to-flap technique to help preserve that epithelium and get those predictable results.”

Patients often misunderstand common medical phrases

Patients frequently misunderstand physician phrases and assign opposite meanings of what was intended, leading to confusion about health outcomes, a study published in JAMA Network Open reported.
Although clinicians acknowledge that medical jargon should be avoided when communicating with patients, they often use it, Rachael Gotlieb, MD, of the University of Minnesota Medical School, and colleagues noted.
“Though this medical language may facilitate communication between health care professionals, its use with patients can introduce confusion that may have serious consequences,”

FDA grants clearance for neurological monitoring device

Medical device company WISE Srl announced the FDA granted clearance for its Cortical Strip, a single-use device intended to be used on the brain surface for intraoperative neurophysiological monitoring.
According to the company’s release, the novel device is the first to receive FDA clearance within the product family and follows the European CE mark already received by the product in May 2021.
The WISE Cortical Strip is intended for intraoperative use with recording, monitoring and stimulation equipment for the recording, monitoring, and stimulation of electrical signals on the brain

KidneyCure 2023 grant program applications open until Dec. 7

The 2023 KidneyCure grant programs are now open until 2 p.m. EST on Dec. 7, according to an American Society of Nephrology press release.
Investigators conducting clinical or basic research are eligible to apply, as are kidney health investigators who are at a key professional development milestone. Overall, there are more than 300 grants available in the four program categories.
The four categories include the Pre-Doctoral Fellowship Program ($30,000 per year for up to 2 years), the Ben J. Lipps Fellowship Program ($50,000 per year for up to 2 years), the William and Sandra Bennett Clinical

Flu hospitalizations hit 12-year high for this time of year

Hospitalizations for influenza are the highest they have been at this time of year since 2010, the CDC reported Friday.
There have been at least 8.7 million illnesses, 78,000 hospitalizations and 4,500 deaths from influenza so far this season in the United States, according to the CDC, with hospitalizations doubling over the course of a week to 19,593 patients in the week ending Nov. 26.
The cumulative hospitalization rate of 16.6 per 100,000 people is the highest for this time of year since the 2010-2011 season, the agency said.
“Seasonal influenza activity is high and continues to

FDA issues ‘study may proceed’ letter for clinical trial for MDD treatment

The FDA has issued a “study may proceed” letter to biopharmaceutical company Vistagen for its newly filed investigational new drug application for the clinical development of PH10, a treatment for major depressive disorder.
The letter greenlights a phase 1 clinical trial of 12 participants that intends to confirm the safety profile of PH10, which was established through three previous clinical trials conducted in Mexico.
“People living with major depressive disorder urgently need new and differentiated therapies — we are committed to addressing that need,” Vistagen

Healthy plant-based diets linked to lower colorectal cancer risk in men

Diets high in healthy plant foods and low in unhealthy plant foods were associated with a lower colorectal cancer risk in men, a recent study published in BMC Medicine found.
“Although screening and treatment for colorectal cancer have improved, new preventive strategies to lower risk remain a priority,” Jihye Kim, a professor in the College of Life and Sciences at Kyung Hee University in South Korea, and colleagues wrote. “Accumulating evidence indicates that diet is an important modifiable risk factor for colorectal cancer.”
According to the researchers, three

CGM use lowers hospitalizations, may reduce mortality in type 1 and type 2 diabetes

Use of continuous glucose monitoring was associated with a lower risk for all-cause hospitalization and mortality in adults with type 1 and type 2 diabetes attending Veterans Affairs clinics in the U.S., according to a speaker.
During a presentation at the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease, Peter Reaven, MD, professor in the division of endocrinology at the University of Arizona College of Medicine and endocrinologist at the Carl T. Hayden VA Medical Center in Phoenix, discussed how CGM can confer benefits for people with diabetes beyond lowering

Long-term PCSK9 inhibition plus background therapy improves LDL goal attainment in FH

Long-term adherence to PCSK9 inhibition was high among a high-risk cohort with familial hypercholesterolemia, which improved LDL goal attainment when added on top of background statin therapy and ezetimibe, researchers reported.
This long-term prospective analysis of the Spanish Familial Hypercholesterolemia Cohort Study (SAFEHEART) was published in the European Journal of Preventive Cardiology.
“Our findings show the difficulty in the attainment of LDL-C goals in patients with familial hypercholesterolemia as they usually have higher baseline LDL-C levels, and that the addition of PCSK9

Dostarlimab-gxly regimen extends PFS in primary advanced or recurrent endometrial cancer

A combination of dostarlimab-gxly and standard-of-care chemotherapy significantly extended PFS compared with placebo and chemotherapy among women with primary advanced or recurrent endometrial cancer, topline data showed.
Researchers observed a statistically significant and clinically meaningful PFS benefit with the dostarlimab-gxly (Jemperli, GSK) regimen in a prespecified subgroup of women with mismatch repair-deficient/microsatellite instability-high disease, as well as among the overall population in part 1 of the randomized, phase 3 RUBY trial, according to a press release from the